Literature DB >> 21164292

MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation.

Robert B West1, Christina Kong, Nicole Clarke, Thea Gilks, Joe S Lipsick, Hongbin Cao, Shirley Kwok, Kelli D Montgomery, Sushama Varma, Quynh-Thu Le.   

Abstract

BACKGROUND: Adenoid cystic carcinoma is a locally aggressive salivary gland neoplasm, which has a poor long-term prognosis. A chromosomal translocation involving the genes encoding the transcription factors, MYB and NFIB, has been recently discovered in these tumors.
METHODS: MYB translocation and protein expression were studied in 37 adenoid cystic carcinomas, 112 other salivary gland neoplasms, and 409 nonsalivary gland neoplasms by fluorescence in situ hybridization and immunohistochemistry. MYB translocation and expression status in adenoid cystic carcinoma was correlated with clinicopathologic features including outcome, with a median follow-up of 77.1 months (range, 23.2 to 217.5 mo) for living patients.
RESULTS: A balanced translocation between MYB and NFIB is present in 49% of adenoid cystic carcinomas but is not identified in other salivary gland tumors or nonsalivary gland neoplasms. There is no apparent translocation of MYB in 35% of the cases. Strong Myb immunostaining is very specific for adenoid cystic carcinomas but is only present in 65% of all cases. It is interesting to note that Myb immunostaining is confined to the basal cell component although the translocation is present in all the cells. Neoplasms with MYB translocation show a trend toward higher local relapse rates, but the results are not statistically significant with the current number of cases.
CONCLUSIONS: MYB translocation and expression are useful diagnostic markers for a subset of adenoid cystic carcinomas. The presence of the translocation may be indicative of local aggressive behavior, but a larger cohort may be required to show statistical significance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21164292      PMCID: PMC3127258          DOI: 10.1097/PAS.0b013e3182002777

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.

Authors:  Idoya Lahortiga; Kim De Keersmaecker; Pieter Van Vlierberghe; Carlos Graux; Barbara Cauwelier; Frederic Lambert; Nicole Mentens; H Berna Beverloo; Rob Pieters; Frank Speleman; Maria D Odero; Marijke Bauters; Guy Froyen; Peter Marynen; Peter Vandenberghe; Iwona Wlodarska; Jules P P Meijerink; Jan Cools
Journal:  Nat Genet       Date:  2007-04-15       Impact factor: 38.330

Review 2.  MYB function in normal and cancer cells.

Authors:  Robert G Ramsay; Thomas J Gonda
Journal:  Nat Rev Cancer       Date:  2008-07       Impact factor: 60.716

3.  Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.

Authors:  Sébastien J Hotte; Eric W Winquist; Elizabeth Lamont; Mary MacKenzie; Everett Vokes; Eric X Chen; Shirley Brown; Gregory R Pond; Anthony Murgo; Lillian L Siu
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

Review 4.  Fusion oncogenes and tumor type specificity--insights from salivary gland tumors.

Authors:  Göran Stenman
Journal:  Semin Cancer Biol       Date:  2005-06       Impact factor: 15.707

5.  A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.

Authors:  Robert B West; Brian P Rubin; Melinda A Miller; Subbaya Subramanian; Gulsah Kaygusuz; Kelli Montgomery; Shirley Zhu; Robert J Marinelli; Alessandro De Luca; Erinn Downs-Kelly; John R Goldblum; Christopher L Corless; Patrick O Brown; C Blake Gilks; Torsten O Nielsen; David Huntsman; Matt van de Rijn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-06       Impact factor: 11.205

6.  Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene.

Authors:  Afrouz Behboudi; Fredrik Enlund; Marta Winnes; Ywonne Andrén; Anders Nordkvist; Ilmo Leivo; Emilie Flaberg; Laszlo Szekely; Antti Mäkitie; Reidar Grenman; Joachim Mark; Göran Stenman
Journal:  Genes Chromosomes Cancer       Date:  2006-05       Impact factor: 5.006

7.  Microtubule-associated protein-2 is a sensitive marker of primary and metastatic neuroblastoma.

Authors:  Chandra Krishnan; John P Higgins; Robert B West; Yasodha Natkunam; Amy Heerema-McKenney; Daniel A Arber
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

8.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.

Authors:  Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

9.  Non-random chromosome rearrangements in adenoid cystic carcinoma of the salivary glands.

Authors:  A Nordkvist; J Mark; H Gustafsson; G Bang; G Stenman
Journal:  Genes Chromosomes Cancer       Date:  1994-06       Impact factor: 5.006

  9 in total
  71 in total

1.  Hybrid Intercalated Duct Lesion of the Parotid: Diagnostic Challenges of a Recently Described Entity with Fine Needle Aspiration Findings.

Authors:  Yingting Mok; Yin Huei Pang; Ming Teh; Fredrik Petersson
Journal:  Head Neck Pathol       Date:  2015-10-17

2.  Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement.

Authors:  T Y Chen; M G Keeney; A V Chintakuntlawar; D L Knutson; S Kloft-Nelson; P T Greipp; J A Garrity; D R Salomao; J J Garcia
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

Review 3.  Molecular biology of adenoid cystic carcinoma.

Authors:  Jia Liu; Chunbo Shao; Marietta L Tan; David Mu; Robert L Ferris; Patrick K Ha
Journal:  Head Neck       Date:  2011-10-17       Impact factor: 3.147

4.  Fusion proteins in head and neck neoplasms: Clinical implications, genetics, and future directions for targeting.

Authors:  Derek A Escalante; He Wang; Christopher E Fundakowski
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

5.  MYB Translocation Status in Salivary Gland Epithelial-Myoepithelial Carcinoma: Evaluation of Classic, Variant, and Hybrid Forms.

Authors:  Justin A Bishop; William H Westra
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

Review 6.  Genetic alterations in salivary gland cancers.

Authors:  Linda X Yin; Patrick K Ha
Journal:  Cancer       Date:  2016-02-29       Impact factor: 6.860

7.  MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.

Authors:  Jisun Kim; Felipe C Geyer; Luciano G Martelotto; Charlotte Ky Ng; Raymond S Lim; Pier Selenica; Anqi Li; Fresia Pareja; Nicola Fusco; Marcia Edelweiss; Rahul Kumar; Rodrigo Gularte-Merida; Andre N Forbes; Ekta Khurana; Odette Mariani; Sunil Badve; Anne Vincent-Salomon; Larry Norton; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Pathol       Date:  2017-12-28       Impact factor: 7.996

8.  [A 75-year-old female patient with pleural effusion and gastric metastases of a poorly differentiated carcinoma].

Authors:  E Roeb; T Dreyer; D Steiner; A Bräuninger; S Gattenlöhner
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

9.  A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.

Authors:  A L Ho; L Dunn; E J Sherman; M G Fury; S S Baxi; R Chandramohan; S Dogan; L G T Morris; G D Cullen; S Haque; C S Sima; A Ni; C R Antonescu; N Katabi; D G Pfister
Journal:  Ann Oncol       Date:  2016-08-26       Impact factor: 32.976

10.  Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract.

Authors:  Justin A Bishop; Takenori Ogawa; Edward B Stelow; Christopher A Moskaluk; Wayne M Koch; Sara I Pai; William H Westra
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.